[1]	Zucca E, Rossi D, Bertoni F. Marginal zone lymphomas[J]. Hematol Oncol, 2023, 41(1):88-91.DOI:10.1002/hon.3152. Cited in this article [1]

[2]	蔡伟欣, 周美玲, 舒凌, 等. 伴单克隆IgM增高的淋巴结边缘区淋巴瘤1例并文献复习[J]. 白血病·淋巴瘤, 2022, 31(12):725-729.DOI:10.3760/cma.j.cn115356-20210825-00195. Cited in this article [1]

[3]	Lee CL, Lee IS, Jung SG. A case of nodal marginal zone B-cell lymphoma of the lower eyelid[J]. Arch Craniofac Surg, 2020, 21(4):249-252.DOI:10.7181/acfs.2020.00241. Cited in this article [1]

[4]	Nakamura S, Ponzoni M. Marginal zone B-cell lymphoma:lessons from Western and Eastern diagnostic approaches[J]. Pathology, 2020, 52(1):15-29.DOI:10.1016/j.pathol.2019.08.012. Cited in this article [1]

[5]	Traverse-Glehen A, Bertoni F, Thieblemont C, et al. Nodal marginal zone B-cell lymphoma:a diagnostic and therapeutic dilemma[J]. Oncology(Williston Park), 2012, 26(1):92-104. Cited in this article [1]

[6]	Dierlamm J, Wlodarska I, Michaux L, et al. Genetic abnormalities in marginal zone B-cell lymphoma[J]. Hematol Oncol, 2000, 18(1):1-13.DOI:10.1002/(sici)1099-1069(200003)18:1<1::aid-hon647>3.0.co;2-g. Cited in this article [1]

[7]	Ikeda J, Kohara M, Tsuruta Y, et al. Immunohistochemical analysis of the novel marginal zone B-cell marker IRTA1 in malignant lymphoma[J]. Human Pathology, 2017, 59:70-79.DOI:10.1016/j.humpath.2016.09.011. Cited in this article [1]

[8]	Khalil MO, Morton LM, Devesa SS, et al. Incidence of marginal zone lymphoma in the United States,2001-2009 with a focus on primary anatomic site[J]. Br J Haematol, 2014, 165(1):67-77.DOI:10.1111/bjh.12730. Cited in this article [1]

[9]

Ferreri AJ, Sassone M, Kiesewetter B, et al. High-dose clarithromycin is an active monotherapy for patients with relapsed/refractory extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue(MALT):the HD-K phase Ⅱ trial[J]. Ann Oncol, 2015, 26(8):1760-1765.DOI:10.1093/annonc/mdv214. Cited in this article [1]

[10]

Hanse A, Reiter K, Pruss A, et al. Dissemination of a Sjögren’s syndrome-associated extranodal marginal-zone B cell lymphoma:circulating lymphoma cells and invariant mutation pattern of nodal Ig heavy- and light-chain variable-region gene rearrangements[J]. Arthritis Rheum, 2006, 54(4):127-137.DOI:10.1002/art.21558. Cited in this article [1]

[11]	Bai SJ, Geng Y, Gao YN, et al. Marginal zone lymphoma with severe rashes:a case report[J]. World J Clin Cases, 2024, 12(3):565-574.DOI:10.12998/wjcc.v12.i3.565. Cited in this article [1]

[12]	刘玉珠. 头颈部原发结外非霍奇金淋巴瘤临床特征分析[D]. 乌鲁木齐: 新疆医科大学, 2021.DOI:10.27433/d.cnki.gxyku.2021.000370. Cited in this article [1]

[13]	曹辉. 头颈部淋巴瘤影像特点及其与病理类型相关性研究[D]. 南京: 南京医科大学, 2020.DOI:10.27249/d.cnki.gnjyu.2020.000336. Cited in this article [1]

[14]	Wang M, Guo Y, Dong L, et al. Coexistence of nodal marginal zone B-cell lymphoma and multiple myeloma:a case report and literature review[J]. Medicine, 2022, 101(17):29219.DOI:10.1097/MD.0000000000029219. Cited in this article [1]

[15]	Laurent C, Cook JR, Yoshino T, et al. Follicular lymphoma and marginal zone lymphoma:how many diseases[J]. Virchows Archiv, 2023, 482(1):149-162.DOI:10.1007/s00428-022-03432-2. Cited in this article [1]

[16]	张洪, 郭晶晶, 潘华雄, 等. 儿童型结内边缘区淋巴瘤一例[J]. 临床内科杂志, 2024, 41(1):60-61.DOI:10.3969/j.issn.1001-9057.2024.01.016. Cited in this article [1]

[17]	Piris MA, Rivas C, Morente M, et al. Monocytoid B-cell lymphoma,a tumour related to the marginal zone[J]. Histopathology, 1988, 12(4):383-392.DOI:10.1111/j.1365-2559.1988.tb01953.x. Cited in this article [1]

[18]	Sheibani K, Sohn CC, Burke JS, et al. Monocytoid B-cell lymphoma.A novel B-cell neoplasm[J]. Am J Pathol, 1986, 124(2):310-318. Cited in this article [1]

[19]	Nathwani BN, Drachenberg MR, Hernandez AM, et al. Nodal monocytoid B-cell lymphoma(nodal marginal-zone B-cell lymphoma)[J]. Semin Hematol, 1999, 36(2):128-138. Cited in this article [1]

[20]	Cousar JB, McGinn DL, Glick AD, et al. Report of an unusual lymphoma arisingfrom parafollicular B-lymphocytes(PBLs) or so-called monocytoid lymphocytes[J]. Am J Clin Pathol, 1987, 87(1):121-128.DOI:10.1093/ajcp/87.1.121. Cited in this article [1]

[21]	Piris MA, Arribas A, Mollejo M. Marginal zone lymphoma[J]. Semin Diagn Pathol, 2011, 21(4):135-145.DOI:10.1053/j.semdp.2011.03.001. Cited in this article [1]

[22]	Jiang S, Manandhar U, Zheng KP, et al. A case of nodal marginal zone lymphoma with hypersensitivity to mosquito bites as initial symptom[J]. J Cutan Pathol, 2019, 46(10):769-774.DOI:10.1111/cup.13497. Cited in this article [1]

[23]

Sesboue C, Galtier J, Jeanneau M, et al. Combined reverse-transcriptase multiplex ligation-dependent probe amplification and next-generation sequencing analyses to assign unclassified BCL2/BCL6 nonrearranged small B-cell lymphoid neoplasms as follicular or nodal marginal zone lymphoma[J]. Mod Pathol, 2023, 36(2):100043.DOI:10.1016/j.modpat.2022.100043. Cited in this article [1]

[24]	Pileri S, Ponzoni M. Pathology of nodal marginal zone lymphomas[J]. Best Pract Res Clin Haematol, 2017, 30(1-2):50-55.DOI:10.1016/j.beha.2016.11.001. Cited in this article [1]

[25]	Van Den Brand M, Van Krieken JH. Recognizing nodal marginal zone lymphoma:recent advances and pitfalls.A systematic review[J]. Haematologica, 2013, 98(7):1003-1013.DOI:10.3324/haematol.2012.083386. Cited in this article [1]

[26]	Dierlamm J, Wlodarska I, Michaux L, et al. Genetic abnormalities in marginal zone B-cell lymphoma[J]. Hematol Onco, 2000, 18(1):1-13.DOI:10.1002/(SICI)1099-1069(200003)18:1<1::AID-HON647>3.0.CO;2-G. Cited in this article [1]

[27]	Diehl V, Borchmann P. Hematology/oncology clinics of North America.Hodgkin lymphoma.Preface[J]. Hematol Oncol Clin North Am, 2014, 28(1): ix-x.DOI:10.1016/j.hoc.2013.10.011. Cited in this article [1]

[28]	Alderuccio JP, Lossos IS. Enhancing prognostication and personalizing treatment of extranodal marginal zone lymphoma[J]. Expert Rev Hematol, 2023, 16(5):333-348.DOI:10.1080/17474086.2023.2206557. Cited in this article [1]

[29]	Cheah CY, Seymour JF. Marginal zone lymphoma:2023 update on diagnosis and management[J]. Am J Hematol, 2023, 98(10):1645-1657.DOI:10.1002/ajh.27058. Cited in this article [1]

[30]	Lasica M, Anderson MA, Boussioutas A, et al. Marginal zone lymphomas:a consensus practice statement from the Australasian Lymphoma Alliance[J]. Intern Med J, 2024, 54(6):1017-1030.DOI:10.1111/imj.16390. Cited in this article [1]

[31]	Zucca E, Arcaini L, Buske C, et al. Marginal zone lymphomas:ESMO clinical practice guidelines for diagnosis,treatment and follow-up[J]. Ann Oncol, 2020, 31(1):17-29.DOI:10.1016/j.annonc.2019.10.010. Cited in this article [1]

[32]	Traverse-Glehen A, Baseggio L, Salles G, et al. Splenic marginal zone B-cell lymphoma:a distinct clinicopathological and molecular entity.Recent advances in ontogeny and classification[J]. Curr Opin Oncol, 2011, 23(5):441-448.DOI:10.1097/CCO.0b013e328349ab8d. Cited in this article [1]

[33]	Zhou X, Wuchter P, Egerer G, et al. Serological hepatitis B virus(HBV)activity in patients with HBV infection and B-cell non-Hodgkin’s lymphoma[J]. Eur J Haematol, 2020, 104(5):469-475.DOI:10.1111/ejh.13388. Cited in this article [1]

[34]	Thieblemont C. Clinical presentation and management of marginal zone lymphomas[J]. Hematology Am Soc Hematol Educ Program,2005:307-313.DOI:10.1182/asheducation-2005.1.307. Cited in this article [1]

[35]	Noy A, de Vos S, Coleman M, et al. Durable ibrutinib responses in relapsed/refractory marginal zone lymphoma:long-term follow-up and biomarker analysis[J]. Blood Adv, 2020, 4(22):5773-5784.DOI:10.1182/bloodadvances.2020003121. Cited in this article [1]

[36]	Berger F, Felman P, Thieblemont C, et al. Non-MALT marginal zone B-cell lymphomas:a description of clinical presentation and outcome in 124 patients[J]. Blood, 2000, 95(6):1950-1956. Cited in this article [1]

[37]	Park JH, Kim S, Ryu JS, et al. Complete metabolic response(CMR)in positron emission tomography-computed tomography(PET-CT)scans may have prognostic significance in patients with marginal zone lymphomas(MZL)[J]. Hematol Oncol, 2018, 36(1):56-61.DOI:10.1002/hon.2414. Cited in this article [1]

[38]	Vaxman I, Bernstine H, Kleinstern G, et al. FDG PET/CT as a diagnostic and prognostic tool for the evaluation of marginal zone lymphoma[J]. Hematol Oncol, 2019, 37(2):168-175.DOI:10.1002/hon.2578. Cited in this article [1]

[39]	Noy A, de Vos S, Thieblemont C, et al. Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma[J]. Blood, 2017, 129(16):2224-2232.DOI:10.1182/blood-2016-10-747345. Cited in this article [1]

[40]	Al-Ibraheem A, Mottaghy FM, Juweid ME. PET/CT in Hodgkin lymphoma: an update[J]. Semin Nucl Med, 2023, 53(3):303-319.DOI:10.1053/j.semnuclmed.2022.10.006. Cited in this article [1]

[41]	Salmeron-Villalobos J, Egan C, Borgmann V, et al. A unifying hypothesis for PNMZL and PTFL:morphological variants with a common molecularprofile[J]. Blood Adv, 2022, 6(16):4661-4674.DOI:10.1182/bloodadvances.2022007322. Cited in this article [1]

[42]	Soriano PK, Stone T, Baqai J, et al. A case of synchronous bone marrow chronic myelomonocytic leukemia(CMML)and nodal marginal zone lymphoma(NMZL)[J]. Am J Case Rep, 2018, 19:1135-1139.DOI:10.12659/AJCR.910583. Cited in this article [1]

[43]	Laurent C, Cook JR, Yoshino T, et al. Follicular lymphoma and marginal zone lymphoma:how many diseases[J]. Virchows Arch, 2023, 482(1):149-162.DOI:10.1007/s00428-022-03432-2. Cited in this article [1]

[44]	Tadmor T, Polliack A. Nodal marginal zone lymphoma: clinical features, diagnosis, management and treatment[J]. Best Pract Res Clin Haematol, 2017, 30(1-2):92-98.DOI:10.1016/j.beha.2016.08.026. Cited in this article [1]

[45]

Opat S, Tedeschi A, Linton K, et al. The magnolia trial:zanubrutinib,a next-generation bruton tyrosine kinase inhibitor,demonstrates safety and efficacy in relapsed/refractory marginal zone lymphoma[J]. Clin Cancer Res, 2021, 27(23):6323-6332.DOI:10.1158/1078-0432.CCR-21-1704. Cited in this article [1]

[46]	Zanoni L, Bezzi D, Nanni C, et al. PET/CT in non-hodgkin lymphoma:an update[J]. Semin Nucl Med, 2023, 53(3):320-351.DOI:10.1053/j.semnuclmed.2022.11.001. Cited in this article [1]

[47]	Kagan KBT, Guz D, Buchrits S, et a. Clinical and pathological predictors for FDG-PET/CT avidity in patients with marginal zone lymphoma-a retrospective cohort study[J]. Eur J Nucl Med Mol Imaging, 2022,49:2290-2299.DOI:10.1007/s00259-022-05683-2. Cited in this article [1]

[48]	Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation,staging,and response assessment of Hodgkin and non-Hodgkin lymphoma:the Lugano classification[J]. J Clin Oncol, 2014, 32(27):3059-3068.DOI:10.1200/JCO.2013.54.8800. Cited in this article [1]

[49]	Qian L, Soderquist C, Schrank Hacker A, et al. Deletion 20q12 is associated with histological transformation of nodal marginal zone lymphoma to diffuse large B - cell lymphoma[J]. Am J Hematol, 2020, 95(3):238-244.DOI:10.1002/ajh.25694. Cited in this article [1]

[50]	Leonard JP, Trneny M, Izutsu K, et al. AUGMENT: a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma[J]. J Clin Oncol, 2019, 37(14):1188-1199.DOI:10.1200/JCO.19.00010. Cited in this article [1]

[51]	Thieblemont C, Davi F, Noguera ME, et al. Non-MALT marginal zone lymphoma[J]. Curr Opin Hematol, 2011, 18(4):273-279.DOI:10.1097/MOH.0b013e3283477815. Cited in this article [1]

[52]	Wang H, Wan X, Zhang Y, et al. Advances in the treatment of relapsed/refractory marginal zone lymphoma[J]. Front Oncol, 2024,14:1327309.DOI:10.3389/fonc.2024.1327309. Cited in this article [1]

[53]	Vanazzi A, Grana C, Crosta C, et al. Efficacy of 90Yttrium-ibritumomab tiuxetan in relapsed/refractory extranodal marginal-zone lymphoma[J]. Hematol Oncol, 2014, 32(1):10-15.DOI:10.1002/hon.2078. Cited in this article [1]

[54]	Stuver R, Drill E, Qualls D, et al. Retrospective characterization of nodal marginal zone lymphoma[J]. Blood Adv, 2023, 7(17):4838-4847.DOI:10.1182/bloodadvances.2022009587. Cited in this article [1]

[55]	Mintz MA, Cyster JG. T follicular helper cells in germinal center B cell selection and lymphomagenesis[J]. Immunol Rev, 2020, 296(1):48-61.DOI:10.1111/imr.12860. Cited in this article [1]

[56]	Kalashnikov I, Tanskanen T, Viisanen L, et al. Transformation and survival in marginal zone lymphoma:a finnish nationwide population-based study[J]. Blood Cancer J, 2023, 13(1):62.DOI:10.1038/s41408-023-00831-9. Cited in this article [1]

[57]	Olszewski A, Jakobsen LH, Collins GP, et al. Burkitt lymphoma international prognostic index[J]. J Clin Oncol, 2021, 39(10):1129-1138.DOI:10.1200/JCO.20.03288. Cited in this article [1]

[58]	Bonnet C, Lejeune M, Van Kemseke C, et al. Prise en charge actueLe du lymphome de la zone marginale[Current management of marginal zone lymphomas][J]. Rev Med Suisse, 2015, 11(483):1549-1556. Cited in this article [1]

[59]	Hoffmann M, Kletter K, Becherer A, et al. 18F-fluorodeoxyglucose positron emission tomography(18F-FDG-PET)for staging and follow-up of marginal zone B-cell lymphoma[J]. Oncology, 2003, 64(4):336-340.DOI:10.1159/000070290. Cited in this article [1]

[60]

de Vos S, Goy A, Dakhil SR, et al. Multicenter randomized phase Ⅱ study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma[J]. J Clin Oncol, 2009, 27(30):5023-5030.DOI:10.1200/JCO.2008.17.7980. Cited in this article [1]

[61]	Kiesewetter B, Troch M, Dolak W, et al. A phase Ⅱ study of lenalidomide in patients with extranodal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue(MALT lymphoma)[J]. Haematologica, 2013, 98(3):353-356.DOI:10.3324/haematol.2012.065995. Cited in this article [1]

[62]

Flinn IW, van der Jagt R, Kahl B, et al. First-line treatment of patients with indolent non-hodgkin lymphoma or mantle-cell lymphoma with bendamustine plus rituximab versus R-CHOP or R-CVP:results of the bright 5-year follow-up study[J]. J Clin Oncol, 2019, 37(12):984-991.DOI:10.1200/JCO.18.00605. Cited in this article [1]

[63]	Ackler S, Oleksijew A, Chen J, et al. Clearance of systemic hematologic tumors by venetoclax(Abt-199)and navitoclax[J]. Pharmacol Res Perspect, 2015, 3(5):e00178.DOI:10.1002/prp2.178. Cited in this article [1]

[64]	Xue JY, Zhao Y, Aronowitz J, et al. Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition[J]. Nature, 2020, 577(7790):421-425.DOI:10.1038/s41586-019-1884-x. Cited in this article [1]

[65]	Gopal AK, Kahl BS, de Vos S, et al. PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma[J]. N Engl J Med, 2014, 370(11):1008-1018.DOI:10.1056/NEJMoa1314583. Cited in this article [1]

[66]	Joshi M, Sheikh H, Abbi K, et al. Marginal zone lymphoma:old,new,targeted,and epigenetic therapies[J]. Ther Adv Hematol, 2012, 3(5):275-290.DOI:10.1177/2040620712453595. Cited in this article [1]

[67]	Arribas AJ, Campos-Martín Y, Gómez-Abad C, et al. Nodal marginal zone lymphoma:gene expression and miRNA profiling identify diagnostic markers and potential therapeutic targets[J]. Blood, 2012, 119(3):9-21.DOI:10.1182/blood-2011-02-339556. Cited in this article [1]

[68]	Thieblemont C, Molina T, Davi F. Optimizing therapy for nodal marginal zone lymphoma[J]. Blood, 2016, 127(17):2064-2071.DOI:10.1182/blood-2015-12-624296. Cited in this article [1]

[69]	Zamò A, van den Brand M, Climent F, et al. The many faces of nodal and splenic marginal zone lymphomas. A report of the 2022 EA4HP/SH lymphoma workshop[J]. Virchows Arch, 2023, 483(3):317-331.DOI:10.1007/s00428-023-03633-3. Cited in this article [1]

[70]	Bommier C, Donzel M, Rossi C, et al. Real-world data for marginal zone lymphoma patients in the French REALYSA cohort: the REALMA study[J]. Hematol Oncol, 2024, 42(6):e3314.DOI:10.1002/hon.3314. Cited in this article [1]

[71]	王培, 王帅亮, 朱华, 等. 放射性核素探针在嵌合抗原受体T细胞治疗显像中的应用[J]. 国际放射医学核医学杂志, 2023, 47(5):302-307.DOI:10.3760/cma.j.cn121381-202206010-00290. Cited in this article [1]